Device Trial Radar · NCT00556608
Efficacy Study of Intra-articular Hyaluronic Acid in the Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Dec 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
381
Actual
Start
Nov 2007
Primary completion
Jul 2009
Study completion May 2010
Sponsor
- Lead sponsor
- IBSA Institut Biochimique SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to prove the non-inferiority of the intra-articular injection of hyaluronic acid (Sinovial®) in the symptomatic treatment of knee OA in comparison to Synvisc®.
Conditions
- Osteoarthritis, Knee
Interventions
Sinovial® (syringe containing sodium hyaluronate solution)Device
2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
Synvisc® ( syringe containing Hylan G-F 20 solution)Device
2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in WOMAC pain subscore from baselineTime frame: to week 26
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Interni hemato-onkologická klinika, Fakultní nemocnice
Brno-Bohunice, Czechia
ARTHROMED s.r.o.
Pardubice, Czechia
Institute of Rheumatology
Prague, Czechia
17 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.